The present invention relates to a transformed T-cell for T-cell therapy, and a composition including same for anticancer immunotherapy. More particularly, the transformed T-cell is characterized by the removal of an intracellular signaling domain of CTLA4 or PD1, which is a surface immune tolerance-induced receptor for a T-cell surface, and by the transfection of a gene for coding a CTLA4-CD28 chimera protein or PD1-CD28 chimera protein to which an intracellular activation transduction domain of CD28, which is T-cell activation surface protein, is bound. The T-cell, to which the gene for coding the CTLA4-CD28 chimera protein or PD1-CD28 chimera protein is transected, can solve the problem of impeded therapeutic effects induced by immune tolerance of cancer cells, and furthermore maximize anti-cancer effects by activating signal transduction of CD28 to induce the activation of T-cells. Also, the activation of CTLA4 or PD1 is inhibited only in cancer cell-specified T-cells, so that it is possible to minimize side effects such as the development of autoimmune diseases due to systematic T-cell activation which may occur in the case where a non-specific CTLA4 or PD1 antagonist is used - for example, a typical anti-CTLA4 antibody.La présente invention concerne un lymphocyte T transformé pour thérapie faisant appel aux lymphocytes T, et une composition en contenant pour immunothérapie anticancéreuse. Plus précisément, ledit lymphocyte T transformé est caractérisé par lélimination dun domaine de signalisation intracellulaire de CTLA4 ou PD1, qui est un récepteur de surface à tolérance immunitaire induite de la surface des lymphocytes T, et par la transfection dun gène codant pour une protéine chimère CTLA4-CD28 ou PD1-CD28 auquel est lié un domaine transduit dactivation intracellulaire de CD28, qui est la protéine de surface dactivation des lymphocytes T. Le lymphocyte T, transfecté par le gène codant pour la protéine chimère CTLA4-CD28 ou PD1-CD28, peut permettre déviter
